CG Oncology (CGON) Stock Overview
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CGON Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
CG Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$62.97 |
| 52 Week High | US$64.67 |
| 52 Week Low | US$14.80 |
| Beta | 1.19 |
| 1 Month Change | 18.61% |
| 3 Month Change | 53.81% |
| 1 Year Change | 142.66% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 69.41% |
Recent News & Updates
Recent updates
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene
Jan 11We're Not Very Worried About CG Oncology's (NASDAQ:CGON) Cash Burn Rate
Jul 16
A First Take On CG Oncology
Jan 10CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
Dec 13CG Oncology: Promising Data, But Looks Expensive
Aug 26CG Oncology Bringing Undervalued Innovation To Bladder Cancer
Jul 09CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 06Shareholder Returns
| CGON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.3% | -0.6% | -2.3% |
| 1Y | 142.7% | 25.1% | 20.4% |
Return vs Industry: CGON exceeded the US Biotechs industry which returned 27.4% over the past year.
Return vs Market: CGON exceeded the US Market which returned 21.2% over the past year.
Price Volatility
| CGON volatility | |
|---|---|
| CGON Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CGON has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CGON's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 142 | Arthur Kuan | cgoncology.com |
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC.
CG Oncology, Inc. Fundamentals Summary
| CGON fundamental statistics | |
|---|---|
| Market cap | US$5.46b |
| Earnings (TTM) | -US$160.99m |
| Revenue (TTM) | US$4.04m |
Is CGON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGON income statement (TTM) | |
|---|---|
| Revenue | US$4.04m |
| Cost of Revenue | US$121.29m |
| Gross Profit | -US$117.25m |
| Other Expenses | US$43.75m |
| Earnings | -US$160.99m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.91 |
| Gross Margin | -2,902.18% |
| Net Profit Margin | -3,985.02% |
| Debt/Equity Ratio | 0.4% |
How did CGON perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 12:11 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CG Oncology, Inc. is covered by 18 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Corinne Johnson | Goldman Sachs |